Bionano Genomics (BNGO)
(Delayed Data from NSDQ)
$1.03 USD
-0.08 (-7.21%)
Updated May 23, 2024 04:00 PM ET
2-Buy of 5 2
F Value B Growth A Momentum D VGM
Price, Consensus and EPS Surprise
BNGO 1.03 -0.08(-7.21%)
Will BNGO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNGO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BNGO
Is AbCellera Biologics (ABCL) Outperforming Other Medical Stocks This Year?
After Plunging -23.84% in 4 Weeks, Here's Why the Trend Might Reverse for Bionano Genomics, Inc. (BNGO)
BNGO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Analysts Estimate Viridian Therapeutics, Inc. (VRDN) to Report a Decline in Earnings: What to Look Out for
Will Bionano Genomics, Inc. (BNGO) Report Negative Q3 Earnings? What You Should Know
QIAGEN (QGEN) Extends the AI-Powered QCI Interpret Software
Other News for BNGO
Lab Instrument Industry Update - New Commercial Entrants
Bionano Announces Three Publications Demonstrating OGM’s Utility for Cell and Gene Therapy
Bionano Genomics announces three publications on OGM
Bionano Genomics price target lowered by $1 at BTIG, here's why
Strong Performance and Strategic Initiatives Underpin Buy Rating for BioNano Genomics